These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 28427202)

  • 1. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
    Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes based on multigene profiling in metastatic breast cancer patients.
    Basho RK; de Melo Gagliato D; Ueno NT; Wathoo C; Chen H; Shariati M; Wei C; Alvarez RH; Moulder SL; Sahin AA; Roy-Chowdhuri S; Chavez-MacGregor M; Litton JK; Valero V; Luthra R; Zeng J; Shaw KR; Mendelsohn J; Mills GB; Tripathy D; Meric-Bernstam F
    Oncotarget; 2016 Nov; 7(47):76362-76373. PubMed ID: 27806348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
    Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
    Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
    Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
    EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
    Moon WK; Chen HH; Shin SU; Han W; Chang RF
    Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
    Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C
    Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
    Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
    Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
    Hagio K; Amano T; Hayashi H; Takeshita T; Oshino T; Kikuchi J; Ohhara Y; Yabe I; Kinoshita I; Nishihara H; Yamashita H
    Sci Rep; 2021 Apr; 11(1):8109. PubMed ID: 33854152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
    Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
    Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
    PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.